Oral Medication Approved for MS in Canada

.

Oral Medication Approved for MS in Canada

Multiple Sclerosis treatment is bound to revolutionize in Canada as drug-maker Novartis Pharmaceutical Canada Inc. announced on Thursday that the first oral medicine for the condition has been approved for use by some patients in the country. The medication will basically help in providing treatment for the symptoms of MS.

The medicine has been named Gilenya and will be available for sale from the 1st of April at pharmaceutical stores across the nation. The medicine will be available for people who have tried another treatment for the condition with poor results.

The chemical name for Gilenya is fingolimod and it will be used for people with the relapsing-remitting form of the condition. According to the figures available, the disease ends up affecting an astounding 75,000 Canadians. People with this variety of the condition are likely to experience new symptoms with severity of older symptoms worsening.

Gilenya will help in reducing flare-ups of people suffering from multiple sclerosis and will also help in reducing the rate of progress. Each capsule of Gilenya contains 0.5 milligrams of the drug and is the most convenient treatment for MS in Canada.

Talking about the development, a Neurologist from Toronto, Dr. Daniel Selchan, said: "The approval of Gilenya is a significant milestone for the Canadian MS community".


Latest News

Telecom Regulatory Authority of India bans Facebook’s Free Basics
Obama Administration's final budget request offers $19 billion for NASA in fisca
Scientists say their discovery may help explain the Great Attractor
Scientists may Confirm Existence of Gravitational Waves Today
Stunning photo of Newborn Star Illuminating Nebula captured
In Spite of Big Loss in Q4 Tesla’s Shares Increased over Rosy Outlook
Gold Jumps as Yellen says the Fed may take a Go Slow Path for Interest Rate Hike
Cracknell supports tax on sugary drinks in the UK
Patients less likely to die with more nurses, study
Gasoline Prices Drop Further in the Midwest and West due to Oversupply
Deutsche Bank Executives Face a Tough Turnaround Plan as Investors Lose Confiden
Viacom Misses Earnings Expectations for the Fifth Straight Quarter; CEO Takes a